Equity Profile
Post-Earnings Recap
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.83 | N/A | -33.44% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.83 | N/A | -33.44% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Overall, management expressed caution regarding future performance. They highlighted ongoing challenges but did not provide detailed insights.
Management did not provide specific revenue guidance for the upcoming quarters.
The company acknowledged challenges in meeting earnings expectations.
The earnings report indicates that Ultragenyx Pharma is facing challenges, as evidenced by the EPS miss. The stock reacted negatively, dropping 2.28% in response to the disappointing results and lack of guidance. Investors may be concerned about the company's future performance without clear direction from management.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
HALOZYME THERAPEUTIC